BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Aragen, UTS to accelerate biologics R&D in Australia

04 March 2020 | News

This partnership between aims at uniting the capabilities, experience, and expertise of two leading organizations

US based Aragen Bioscience which is a fully owned subsidiary of Hyderabad based GVK BIO and University of Technology Sydney (UTS), the top-ranked young university in Australia has announced a collaboration to accelerate biologics R&D in Australia.

This partnership between UTS and Aragen aims at uniting the capabilities, experience, and expertise of two leading organizations to assist the Australian biopharma and biotech industries advance their ideas into medicines.

Dr. Axel Schleyer, CEO, Aragen Bioscience said, “Under this collaboration, customers can leverage Aragen’s proprietary, cutting edge, royalty-free CHO DG-44 expression system for therapeutic antibody production. Downstream clinical development and manufacturing requirements can be met through UTS’s Biologics Innovation Facility (BIF), providing the Australian Biopharmaceutical Industry with a seamless solution from Concept through Clinic.”

Manni Kantipudi, Chairman, Aragen, & Chief Executive Officer, GVK BIO said, “We are delighted to partner with one of the top Australian institutions - UTS which has the infrastructure and knowhow to support large molecule clinical development. The Aragen team is recognized globally for its antibody research, having discovered three Novel Biological Entities (NBE’s) that are now commercial. Through this collaboration with UTS, we expect to support the local industry by bringing together knowhow, experience, and world class infrastructure that marries speed, innovation, and costs.”

Dr Andrew Groth, UTS Faculty of Science Business Development Manager said, “UTS welcomes the strategic partnership with Aragen to provide comprehensive but affordable cell line and expression technology solutions to Australian research communities and start-ups, to tackle the critical bottleneck during pre- and early-clinical stages of biologics development.”